CE mark of approval given to femtosecond laser platform

Article

The VICTUS femtosecond laser platform has received the CE mark of approval.

The VICTUS femtosecond laser platform has received the CE mark of approval.

Bausch + Lomb collaborated with Technolas Perfect Vision to secure the CE mark approval. The VICTUS laser platform is currently approved for LASIK flap, astigmatic keratotomy, INTRACOR, capsulotomy and lens fragmentation.

The two companies will globally promote VICTUS using their combined commercial skills and cataract and refractive expertise.

Dr Kristian Hohla, CEO of Technolas Perfect Vision, explained, "Our focus has been to empower ophthalmic surgeons with the latest advances in laser technology in order to potentially provide patients with better outcomes and quality of life. We are very pleased that, together with Bausch + Lomb, we have demonstrated the viability of the VICTUS platform for enhances cataract surgery."

President and CEO of Global Surgical Business for Bausch + Lomb, Robert E. Grant, said, "This CE mark approval represents a major step for femtosecond laser technology by elevating the role that laser technology can play in refractive and cataract procedures. I am excited that we will begin shipping this product by the end of next year."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.